Evidence map›Paper›PMID 40361138›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy.

Gresa Emurlai, Randi M Pose, Nikhil Kalra, Cornelia Coith, Sandra Lenz, Pierre Tennstedt, Markus Graefen, Stefan Werner, Sabine Riethdorf, Derya Tilki and 2 more

Abstract readComparative Study
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gresa EmurlaiDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Randi M PoseMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Nikhil KalraDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Cornelia CoithDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Sandra LenzDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Pierre TennstedtMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Markus GraefenMartini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Stefan WernerDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Sabine RiethdorfDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Derya Tilki *Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Simon A Joosse *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany.
Klaus Pantel *Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, Hamburg, 20246, Germany. pantel@uke.de.

Funding

European Research Council 834974
6 · The paper itself

Abstract

backgroundThe potential influence of radical prostatectomy on tumor cell release into the blood circulation is an under-investigated area.

methodsOne hundred three treatment-naïve patients with early-stage prostate cancer were recruited. Blood from the prostatic venous plexus was analyzed for the local release of tumor cells during radical prostatectomy. Simultaneously, systemic spread was assessed by the presence of circulating tumor cells (CTCs) in peripheral venous blood using both the EpCAM-dependent CellSearch and the size-dependent Parsortix systems in parallel. Tumor cells in the plexus blood and CTCs were detected by epithelial keratin expression and lack of CD45 leukocyte antigen.

resultsMedian counts of Keratin + /CD45- cells detected in peripheral blood with the CellSearch and Parsortix systems differed significantly (p = 0.0067) with higher sensitivity of the Parsortix System (16 vs 32% positive findings). Even if the results of both assays were combined, the median number of Keratin + /CD45- cells in the prostatic plexus blood was significantly higher than in the peripheral blood (97 vs. 2 per 7.5 ml, respectively, p < 0.0001). Keratin + /CD45- cells could be identified in 85% of prostate cancer patients in the prostatic plexus blood and in 42% of patients in peripheral blood during surgery without any significant correlation. Keratin + /CD45- cell clusters were identified in the prostatic plexus in 51.2% of patients but neither these clusters nor single Keratin + /CD45- cells were associated with biochemical relapse during follow-up. The presence (p = 0.0094) and number (p = 0.0153) of CTCs in the peripheral blood was significantly associated with PSA levels at initial diagnosis. Single-cell genome-wide sequencing by NGS showed copy number alterations (CNAs) in 15 out of 26 index CTCs originating from both the prostatic plexus and peripheral blood compartments.

conclusionCombining different CTC enrichment principles increases the CTC detection rate in the peripheral blood of early-stage prostate cancer patients. Our study provides first evidence for a considerable local release of normal and malignant epithelial cells during prostatectomy, which, however, was neither associated with increased CTC detection in the peripheral blood nor with early biochemical recurrence. Longer follow up studies are required to assess whether local tumor cell spread might contribute to clinical outcome in prostate cancer.

Indexed as

Neoplastic Cells, CirculatingProstateProstatic NeoplasmsAgedBiomarkers, TumorHumansKeratinsMaleMiddle AgedProstatectomyBiomarkers, TumorKeratins

Identifiers

PMID40361138
PMCPMC12070612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.